M A J O R A R T I C L E
Influence of Leishmania (Viannia) Species on the Response to Antimonial Treatment in Patients with American Tegumentary Leishmaniasis (known as "espundia"). L. (V.) peruviana is mostly encountered in the rural Andean and inter-Andean valleys (between 1000 and 3000 m above sea level), whereas the 2 other species are both endemic in sylvatic regions. However, this epidemiological picture can be affected by environmental changes and human migrations [8] .
Chemotherapy is the main control strategy for leishmaniases, and pentavalent antimonials (Sb V ) are the first-line drugs. Unfortunately, the increasing trend of treatment failure documented in several field sites is now challenging the clinical value of Sb V therapy [9] . Studies conducted in Latin America have reported a range of efficacies of this drug against CL: 7% treatment failure in Bolivia [10] , 16% in Brazil [11] , and up to 39% in Colombia [12] . The identification of the factors associated with chemotherapy failure would allow better clinical management of patients. 
PATIENTS, MATERIALS, AND METHODS
Treatment and follow-up. Peruvian patients with a clinical diagnosis of leishmaniasis were recruited into the Leishnatdrug-R study between November 2001 and December 2004 at the Instituto de Medicina Tropical "Alexander von Humboldt," a national reference center for patients with leishmaniasis. The Leishnatdrug-R study was conducted to assess the occurrence of natural resistance among Leishmania isolates obtained from patients who either responded to treatment or experienced treatment failure with Sb V (20 mg/kg/day intravenous Sb V for 20 days [13] ). Patients were interviewed to identify the most probable geographic origin of infection. They were treated with generic sodium stibogluconate (SSG) from Colombia (Viteco SA;
) or India (Albert David Ltd.; ), depending n p 80 n p 23 on drug availability. All used batches contained the recommended Sb V concentration (quality control was performed by the International Dispensary Association). Patients received antimonial treatment under supervision and attended follow-up visits 1, 3, and 6 to 12 months after treatment. Patients with treatment failure received either (1) a repeat course of antimonials with or without topical imiquimod (Aldara; 3M Pharmaceuticals) or (2) intravenous amphotericin B (amphotericin B deoxycholate; Bristol-Myers Squibb).
Only patients with a first diagnosis of CL without concomitant mucosal involvement, who received у20 doses of antimonials, and who were followed for у6 months were included in the present study. Written, informed consent was obtained from all patients or their parents or guardians. Research protocols complied with national and international ethics policies. The human experimentation guidelines of the Institute of Tropical Medicine Antwerp were followed. Ethics clearance was obtained from the ethical committees of the Universidad Peruana Cayetano Heredia and the Institute of Tropical Medicine Antwerp.
Definition of clinical outcomes. Initial cure (р3 months after treatment) was defined as follows: for ulcers, complete scarring of lesion(s) and disappearance of inflammatory signs; for nodular lesions, flattening and the absence of infiltration or other sign(s) of inflammation. Unresponsiveness was defined as the absence or incomplete scarring of lesion(s) and/or the persistence of inflammatory signs 3 months after treatment or the worsening of existing lesion(s) or the appearance of new lesion(s) р3 months after treatment. Relapse was defined as the reappearance of an ulcer or nodule and/or local signs of inflammation after initial cure. Treatment failure was defined as unresponsiveness or relapse. Cure was defined as initial cure without relapse р12 months after treatment.
Parasite isolation and biopsy handling. Parasite samples (lesion aspirate samples and/or biopsy samples) were collected. Aspirate samples were cultured in Tobie blood agar medium [14] at 23ЊC. Mass cultures were harvested and cryopreserved for species identification. DNA was extracted by use of the QIAmp DNA Mini Kit (Qiagen) or by the classic phenol/chloroform method. For biopsy samples, frozen specimens were lysed at 65ЊC for 3 h in 50 mL of TNE buffer (25 mmol/L Tris, 100 mmol/L NaCl, and 5 mmol/L EDTA [pH 8]) containing 5% sodium dodecyl sulfate and 200 mg/mL proteinase K. After ethanol precipitation, DNA pellets were resuspended in 15 mL of buffer TE (10 mmol/L Tris and 1 mmol/L EDTA [pH 7.4]) [15] .
Parasite species identification. Leishmania species typing was performed by multilocus polymerase-chain-reaction (PCR) restriction fragment-length polymorphism (RFLP) analysis. The target genes rDNA ITS, gp63, hsp70, H2B, and cpb were amplified and digested as reported elsewhere [15] [16] [17] . Restriction patterns were resolved by capillary electrophoresis (2100 Bioanalyzer system; Agilent Technologies) in a microchip device (DNA 1000 LabChip; Caliper Technologies) or by use of 12% polyacrilamide at 29:1, with silver stain. Obtained patterns were compared with those of reference strains of L. (V.) braziliensis 
RESULTS
A total of 171 patients received a diagnosis of leishmaniasis and had the infecting species of Leishmania typed during the study period. Of these patients, 56 did not meet eligibility criteria: 14 had previously received treatment for leishmaniasis, 18 presented concomitant mucosal involvement, 10 did not complete the first round of Sb V treatment, and 14 presented an unclear clinical outcome (i.e., follow-up of !6 months). Twelve patients treated with meglumine antimoniate (Glucantime) or generic SSG from Peru (Marfan) were also excluded from the analysis, because they were too few in number for statistical comparison. Of the 103 patients enrolled in the study, 79 and 24 patients had Leishmania parasites isolated and typed from skin lesion aspirate and biopsy samples, respectively.
Geographic distribution of characterized Leishmania species. The geographic distribution of the selected Leishmania isolates covered all of the Peruvian territory in which leishmaniasis has ). P p .07
DISCUSSION
In the present study, we assessed the influence that Leishmania (V.) species has on the outcome of Sb V therapy in patients with CL in Peru. Our data support there being a significant association between the infecting Leishmania species and treatment outcome. The proportion of treatment failure in patients infected with L. (V.) braziliensis was significantly much higher than that in patients infected with L. (V.) guyanensis, after adjustment for potential confounding factors.
The influence of Leishmania species on treatment outcome has been documented with different drugs in different regions of endemicity (table 1) . Our finding of a higher probability of therapeutic failure in patients infected with L. (V.) braziliensis than in those infected with L. (V.) guyanensis contrasts with the report of Romero et al. [18] , in which the proportion of treatment failure after 6 months of antimonial therapy (Glucantime) was significantly higher in patients infected with L. Some Leishmania species are known to present differing intrinsic susceptibility to antimonials [22] . We recently found clinical isolates of L. (V.) braziliensis and L. (V.) guyanensis that were either susceptible or highly tolerant to Sb V [23] . Accordingly, one might assume that the proportion of Sb V -tolerant L. (V.) guyanensis isolates might vary geographically and explain the differences in treatment outcome encountered with this species between Brazil and Peru. However, in our previous report, we did not find any correlation between parasite Sb V susceptibility (as measured in the in vitro amastigote-macrophage model) and treatment outcome [23] . Furthermore, 2 patients infected with L. (V.) guyanensis showed a definite cure (after follow-up during 12 months), despite being infected with parasites highly tolerant to Sb V [23] . This highlights the need for comparative multicentric and multidisciplinary studies addressing both the host and the parasite, with standardized protocols and definitions.
Our results also provided an updated insight into the distribution of Leishmania species in Peru. A previous report from 1998 [3] was based on multilocus enzyme electrophoresis. Globally, this report and the present study are in agreement, such as the relevant finding of sympatric circulation of L. (V.) braziliensis and L. (V.) guyanensis in the east-central region of the Andes (Departments of Junin, Huanuco, San Martin, and Ucayali). Two specific differences, however, exist. First, the reported proportion of L. (V.) guyanensis isolates from the departments mentioned above increased from 25% (1986) (1987) (1988) (1989) (1990) (1991) (1992) (1993) to 55% (2001) (2002) (2003) (2004) . Second, some species were encountered in unexpected regions, such as L. (V.) peruviana in the Amazonian jungle and L. (V.) braziliensis in the Andes. Differences in study design might explain this variation in frequency; in particular, part of our species identification was performed directly on patient biopsy samples, avoiding the selection biases introduced by isolation and in vitro maintenance. However, comparison of both reports might be indicative of a real change in epidemiological patterns, a phenomenon that is well described in Latin America [24] . Altogether, these results emphasize the need to conduct continuous prospective studies in Peru as well as in many other countries of the subcontinent.
In conclusion, our study demonstrates the complex and dynamic epidemiology of ATL in Peru, a situation that probably occurs in other countries of Latin America. Furthermore, the link between Leishmania species and treatment outcome highlights the relevance of incorporating species typing to improve the clinical management of patients. Moreover, species typing is needed for epidemiological surveys conducted within control programs and for clinical trials. Thus, rapid and very specific methods for parasite identification are urgently needed. PCRbased genotyping methods, such as multilocus PCR-RFLP analysis [15] and multilocus sequence typing [25] , have been developed and can be applied directly to biopsy samples. Nevertheless, they are still too cumbersome to be applied in areas of endemicity that lack sophisticated equipment. Simplification of these characterization tools is needed for their clinical use in endemic regions in which several Leishmania species can coexist (as is the case in Central and South America) but also in travel medicine, in which a clinician can be confronted with different species and the geographic location cannot be used as the only criterion for species discrimination.
